WallStSmart

Quest Diagnostics Incorporated (DGX)vsDanaher Corporation (DHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 117% more annual revenue ($25.11B vs $11.56B). DHR leads profitability with a 16.0% profit margin vs 9.2%. DHR appears more attractively valued with a PEG of 1.15. DHR earns a higher WallStSmart Score of 66/100 (B-).

DGX

Buy

60

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.37

DHR

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.36
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DGX.

DHRSignificantly Overvalued (-66.7%)

Margin of Safety

-66.7%

Fair Value

$117.88

Current Price

$199.63

$81.75 premium

UndervaluedFair: $117.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DGX0 strengths · Avg: 0/10

No standout strengths identified

DHR4 strengths · Avg: 8.8/10
EPS GrowthGrowth
59.7%10/10

Earnings expanding 59.7% YoY

Market CapQuality
$125.93B9/10

Large-cap with strong market position

Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.26B8/10

Generating 1.3B in free cash flow

Areas to Watch

DGX1 concerns · Avg: 4.0/10
PEG RatioValuation
1.944/10

Expensive relative to growth rate

DHR2 concerns · Avg: 3.5/10
P/E RatioValuation
34.7x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : DGX

Revenue growth of 10.2% demonstrates continued momentum.

Bull Case : DHR

The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : DGX

The primary concerns for DGX are PEG Ratio.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Return on Equity.

Key Dynamics to Monitor

DGX profiles as a value stock while DHR is a mature play — different risk/reward profiles.

DHR carries more volatility with a beta of 0.82 — expect wider price swings.

DGX is growing revenue faster at 10.2% — sustainability is the question.

DHR generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

DHR scores higher overall (66/100 vs 60/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quest Diagnostics Incorporated

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Want to dig deeper into these stocks?